Table 1. Potency of GNF7686 and prototypic cytochrome b Inhibitors on wild-type (WT) and GNF7686-resistant (DR) T. cruzi morphological forms.

	Amastigote EC50 [μM]		Epimastigote EC50 [μM]		Trypomastigote EC50 [μM]
Compound	WT	DR	WT	DR	WT	DR
GNF7686	0.15 ± .03*	0.66 ± 0.12*	0.16 ± 0.02*	0.73 ± 0.04*	0.71 ± 0.16*	4.5 ± 0.84*
Antimycin A	N.A.	N.A.	0.046 ± 0.01*	1.8 ± 0.21*	0.20 ± 0.04*	4.3 ± 1.3*
Myxothiazol	N.A.	N.A.	0.49 ± 0.05	0.43 ± 0.08	2.9 ± 0.48	2.9 ± 0.43
Strobilurin	N.A,	N.A.	0.59 ± 0.13	0.34 ± 0.01	1.7± 0.41	1.4 ± 0.36
Benznidazole	1.4 ± 0.17	0.82 ± 0.13	5.5 ± 0.15	6.7 ± 0.6	13± 1.8	11 ± 0.58

EC₅₀ values were calculated from three independent repeats (n = 3), each performed in duplicate. Standard error values are also shown. N.A. in the table stands for ‘not applicable’.

*P-value for wild-type versus drug-resistant T. cruzi EC₅₀ values is < 0.05.